<DOC>
	<DOC>NCT00837811</DOC>
	<brief_summary>To evaluate the safety and tolerability of LY2127399 administered as subcutaneous injections for 48 weeks in patients with Rheumatoid Arthritis</brief_summary>
	<brief_title>An Open Label Extension Study in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have given written informed consent Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation Have participated in either Study BCDG or Study BCDH Have had, during Study BCDG or Study BCDH, any safety event,(including having a recent, ongoing, or serious infection, a serious drug reaction, or any AE that caused discontinuation from treatment) that in the opinion of the investigator poses an unacceptable risk to participation in the study. Have received, during Study BCDG or Study BCDH, any drug not allowed by the study protocol including unapproved drugs, biologic DMARDs, or live vaccines. Enrollment in any other clinical trial involving offlabel use of an investigational drug or device, or enrollment in any other type of medical research.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Arthritis</keyword>
</DOC>